Published in Clin Oncol (R Coll Radiol) on July 17, 2013
The potential and hurdles of targeted alpha therapy - clinical trials and beyond. Front Oncol (2014) 0.90
Targeted Radionuclide Therapy of Human Tumors. Int J Mol Sci (2015) 0.83
Glutathione deficiency and radiosensitivity in AIDS patients. Lancet (1991) 1.51
Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation. Cell Death Dis (2012) 1.32
Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis (1992) 1.05
Expression trapping: identification of novel genes expressed in hematopoietic and endothelial lineages by gene trapping in ES cells. Blood (1998) 0.95
DNA repair capacity as a possible biomarker of breast cancer risk in female BRCA1 mutation carriers. Br J Cancer (2007) 0.85
Can γH2AX be used to personalise cancer treatment? Curr Mol Med (2013) 0.83
Distress associated with radiotherapy for malignant disease: a quantitative analysis based on patients perceptions. Br J Cancer (1989) 0.82
Locoregional treatments for triple-negative breast cancer. Ann Oncol (2012) 0.79
Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine. Cancer Chemother Pharmacol (2000) 0.77
Ascites induced by interleukin-2 in the treatment of renal cancer. Br J Urol (1990) 0.75
Early experience with combined interstitial hyperthermia and brachytherapy. Br J Radiol (1986) 0.75